1. Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М.: Анко, 2000.
2. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009.
3. Lain L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessary? Rew Gastroenterol Dis 2004; 4: 33–41.
4. Fries J, Kristen N, Bennet M et al. The rise and decline of nonsteroidal anti-inflammatory drag-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2433–40.
5. Сороцкая В.Н., Каратеев А.Е. Желудочно-кишечные осложнения как одна из причин смерти больных ревматическими заболеваниями. Науч.-практ. ревматол. 2005; 4: 34–8.
6. Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска. Тер. архив. 2008; 5: 62–6.
7. Simon D, Botting R, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387–437.
8. Grosser T, Fries S, FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibi-tion: therapeutic challenes an opportunities. J Clin Invest 2006; 16: 41.
9. Hochman J, Shah N. What Price Pain Relief? Circulation 2006; 113: 2868–70.
10. Hermann M. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep 2009; 11 (1): 31–5.
11. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 18; 368 (9549): 1771–81.
12. Wang P, Avorn J, Brookhart M et al. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension 2005; 46 (2): 273–9.
13. Алексеева Л.И., Верткин А.Л., Иванов В.С. и др. Остеоартроз в практике врача-терапевта. РМЖ. 2008; 16 (7): 476–81.
14. Lanas A., Tornero J, Zamorano J. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis 2010; 69 (8): 1453–8.
15. Ziegler S, Huscher D, Karberg K et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative arthritis Centers. ARD 2010; 69: 1803–8.
16. Иммаметдинова Г.Р., Чичасова Н.В. Вольтарен в практике ревматолога. РМЖ. 2007; 15 (26): 1987–91.
17. Каратеев А.Е., Насонов Е.Л. НПВП-ассоциированная патология ЖКТ: реальное состояние дел в России. РМЖ. 2006; 15: 1073–8.
18. Brun J, Jones R. Nonsteroidal anti-inflammatory drug-associated dyspepsia: the Scale of the problem. Am J Med 2001; 110: 12–3.
19. Hollenz M, Stolte M, Leodolter A, Labenz J. NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care. Dig Dis 2006; 24 (1–2): 189–94.
20. Каратеев А.Е., Насонов Е.Л., Корешков Г.Г. НПВП-индуцированная диспепсия: распространенность и возможность медикаментозной коррекции. Науч.-практ. ревматол. 2003; 5: 76–8.
21. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006; 296: 1633–44.
22. Fosbøl E, Folke F, Jacobsen S et al. Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals Circ Cardiovasc Qual Outcomes 2010; 3: 395–405.
23. Каратеев А.Е., Насонова В.А. НПВП-ассоциированная гепатопатия: проблема нимесулида. Научн.-практ. ревматол. 2004; 1: 34–7.
24. Banks A, Zimmerman H, Isshak K, Harter J. Diclofenak-associated hepatotoxicity: analysis of 180 cases report to the Food and Drug Administration as adverse reactions. Hepatology 1995; 22: 820–70.
25. Traversa G, Bianchi C, Da Cas R et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003; 327: 18–22.
26. Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. Hepatic disorders in patient treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports. Clinical Therapeutics 2006; 28 (8): 1123–32.
27. Veys E. 20 years’ experience with ketoprofen. Scand J Rheumatol Suppl 1991; 90 (Suppl.): 1–44.
28. Sarzi-Puttini P, Atzeni F, Lanata L et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo 2010; 62 (3): 172–88.
29. Moselli N, Cruto M, Massucco P et al. Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain. Clin J Pain 2010; 26 (4): 267–74.
30. Kokki H, Kokki M. Dose-finding studies of ketoprofen in the management of fever in children: report on two randomized, single-blind, comparator-controlled, single-dose, multicentre, phase II studies. Clin Drug Investig 2010; 30 (4): 251–8.
31. Kawai S, Uchida E, Kondo M et al. Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 2010; 50 (10): 1171–9.
32. Venegoni M, Da Cas R, Menniti-Ippolito F, Traversa G. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. Ann Ist Super Sanita 2010; 46 (2): 153–7.
33. http://www.vidal.ru/poisk_preparatov/ketonal-duo.htm
34. Barden J, Derry S, McQuay H, Moore R. Single dose oral ketoprofen and dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; 4: CD007355.
35. Karvonen S, Salomäki T, Olkkola K. Efficacy of oral paracetamol and ketoprofen for pain management after major orthopedic surgery. Methods Find Exp Clin Pharmacol 2008; 30 (9): 703–6.
36. J Olson N, Otero A, Marrero I et al. Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain. Clin Pharmacol 2001; 41 (11): 1238–47.
37. Dib M, Massiou H, Weber M et al. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 2002; 58 (11): 1660–5.
38. Altman R, Honig S, Levin J, Lightfoot R. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15 (9): 1422–6.
39. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl 1989; 83: 21–7.
40. Schattenkirchner M. Long-term safety of ketoprofen in an elderly population of arthritic patients. Scand J Rheumatol Suppl 1991; 91: 27–36.
41. Dougados M, Béhier J, Jolchine I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44 (1): 180–5.
42. Henry D, Lim L, Garcia Rodriguez L et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563–6.
43. Helin-Salmivaara A, Saarelainen S, Gronroos J et al. Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scan J Gastroenterol 2007; 42: 923–32.
44. Чичасова Н.В., Иммаметдинова Г.Р., Каратеев А.Е. и др. Эффективность и безопасность кетопрофена (кетонал) при ревматоидном артрите (клинико-эндоскопическое исследование). Науч.-практ. ревматол. 2001; 1: 47–52.
45. Лазебник Л.Б., Дроздов В.Н., Коломиец Е.В. Сравнительная эффективность и безопасность применения кетопрофена, лорноксикама, нимесулида и целекоксиба у больных остеоартрозом. РМЖ. 2004; 12 (14): 844–7.
46. Осипова Н.А., Петрова В.В., Ермолаев П.М., Береснев В.А. Нестероидные противовоспалительные препараты в лечении послеоперационной боли у онкологических больных. Фарматека. 2006; 6 (121).
47. Шмидт Е.И., Коган К.М., Белозерова И.В. Оценка эффективности кетоналаретард у больных остеоартрозом. Науч.-практ. ревматол. 2000; 2: 77–9.
48. Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis; selectivity is with patients, not the drug. Ann Rheum Dis 2005; 64 (Suppl. 3): 85.
49. Solomon D, Glynn R, Levin R, Avorn J. Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction. Arch Intern Med 2002; 162: 1099–104.
50. Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospatalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart J 2006; 27: 1657–63.

А.Е.Каратеев 

НИИ ревматологии РАМН, Москва